Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Functional Imaging of Cerebellar Mutism Syndrome

Completed

Conditions: Brain Mass

Interventions: Procedure: MRI with DTI and fMRI

First Posted Date: 2012-11-26

Last Posted Date: 2021-10-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT01733173

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Aerobic Training in Metastatic Breast Cancer

Not Applicable

Completed

Conditions: Metastatic Breast Cancer

Interventions: Behavioral: Nonlinear Aerobic Training
Behavioral: Progressive Stretching Group
Other: Blood draw
Other: Cardiopulmonary Exercise Testing (CPET)

First Posted Date: 2012-11-14

Last Posted Date: 2023-04-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 27

Registration Number: NCT01725633

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)

Phase 1

Completed

Conditions: Breast Cancer
Brain Metastases

Interventions: Radiation: Whole Brain Radiotherapy (WBRT)
Drug: Sorafenib

First Posted Date: 2012-11-12

Last Posted Date: 2022-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 21

Registration Number: NCT01724606

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 3 locations

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Phase 1

Completed

Conditions: Head and Neck Cancer
Squamous Cell Cancer

Interventions: Drug: Afatinib, Ribavirin, and weekly carboplatin/paclitaxel

First Posted Date: 2012-11-04

Last Posted Date: 2017-10-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT01721525

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States

Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer

Not Applicable

Completed

Conditions: Women at Increased Risk for Developing Breast Carcinoma

Interventions: Other: Mammography (CESM) and MRI

First Posted Date: 2012-10-29

Last Posted Date: 2018-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1000

Registration Number: NCT01716247

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

Phase 2

Completed

Conditions: Hairy Cell Leukemia

Interventions: Drug: Vemurafenib

First Posted Date: 2012-10-22

Last Posted Date: 2024-08-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 36

Registration Number: NCT01711632

Locations: 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Acupuncture for Chronic Lymphedema

Phase 2

Completed

Conditions: Breast Cancer With Chronic Lymphedema

Interventions: Procedure: Wait-list
Procedure: Acupuncture

First Posted Date: 2012-10-15

Last Posted Date: 2019-08-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 82

Registration Number: NCT01706081

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)

Phase 1

Recruiting

Conditions: Lymphoma
Solid Malignancy

Interventions: Drug: [18F] 4-L-Fluoroglutamine (2S,4R)

First Posted Date: 2012-10-02

Last Posted Date: 2024-08-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 85

Registration Number: NCT01697930

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Safety Study Assessing the Effects of Receiving Genome Sequencing Results

Completed

Conditions: History of Cancer

Interventions: Behavioral: qualitative interviews

First Posted Date: 2012-09-25

Last Posted Date: 2018-08-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 8

Registration Number: NCT01692223

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Ipilimumab

First Posted Date: 2012-09-20

Last Posted Date: 2024-10-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 57

Registration Number: NCT01688492

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy